Emerging roles for antiangiogenesis factors in management of ocular disease | Zendy

Muhammad Usman Saeed | Zendy; Gkaragkani | Zendy; Ali | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Emerging roles for antiangiogenesis factors in management of ocular disease

Author(s) -

Muhammad Usman Saeed,

Gkaragkani,

Ali

Publication year - 2013

Publication title -

clinical ophthalmology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.025

H-Index - 56

eISSN - 1177-5483

pISSN - 1177-5467

DOI - 10.2147/opth.s31016

Subject(s) - pegaptanib , medicine , aflibercept , ranibizumab , bevacizumab , retinopathy of prematurity , macular degeneration , ophthalmology , choroidal neovascularization , population , disease , chemotherapy , pregnancy , environmental health , biology , genetics , gestational age

The first antivascular endothelial growth factor (anti-VEGF) was developed as an anticancer drug for colonic carcinomas. Since then, anti-VEGFs have developed in scope and indications. They have revolutionized the treatment of exudative macular degeneration and have had a major impact on treatment of several other conditions. This has resulted in an increased number of patients seeking treatment with new treatment options and has had a considerable financial impact on health care resources. Anti-VEGFs have been used in the treatment of all age groups of the population ranging from infants where it is used for treatment of retinopathy of prematurity to the elderly where it is used in exudative macular eegeneration.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research